Coya Therapeutics Management
Management criteria checks 1/4
Coya Therapeutics' CEO ist Howard Berman , ernannt in Jan 2020, hat eine Amtszeit von 4.08 Jahren. Die jährliche Gesamtvergütung beträgt $598.13K , bestehend aus 69% Gehalt und 31% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 6.59% der Aktien des Unternehmens, im Wert von $5.60M . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 1.4 Jahre bzw. 2.7 Jahre.
Key information
Howard Berman
Chief executive officer
US$598.1k
Total compensation
| CEO salary percentage | 69.0% |
| CEO tenure | 4.3yrs |
| CEO ownership | 6.5% |
| Management average tenure | 1.6yrs |
| Board average tenure | 2.8yrs |
Recent management updates
Recent updates
Coya Therapeutics (NASDAQ:COYA) Is In A Good Position To Deliver On Growth Plans
Mar 26
Coya Therapeutics In Catbird Seat Following Dr. Reddy's Licensing Deal
Feb 13Coya Therapeutics: Interesting Early Data In CNS Diseases, Very Low Cash Position
Jan 13We Think Coya Therapeutics (NASDAQ:COYA) Needs To Drive Business Growth Carefully
Sep 06Here's Why We're Watching Coya Therapeutics' (NASDAQ:COYA) Cash Burn Situation
May 17CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | n/a | n/a | -US$8m |
| Sep 30 2023 | n/a | n/a | -US$12m |
| Jun 30 2023 | n/a | n/a | -US$13m |
| Mar 31 2023 | n/a | n/a | -US$13m |
| Dec 31 2022 | US$598k | US$413k | -US$12m |
| Sep 30 2022 | n/a | n/a | -US$11m |
| Jun 30 2022 | n/a | n/a | -US$8m |
| Mar 31 2022 | n/a | n/a | -US$6m |
| Dec 31 2021 | US$390k | US$300k | -US$5m |
Vergütung im Vergleich zum Markt: HowardDie Gesamtvergütung ($USD598.13K) liegt im Durchschnitt der Unternehmen ähnlicher Größe auf dem Markt US ($USD738.70K).
Entschädigung vs. Einkommen: HowardDie Bezüge der Mitarbeiter sind gestiegen, während das Unternehmen unrentabel ist.
CEO
Howard Berman (49 yo)
4.3yrs
Tenure
US$598,125
Compensation
Dr. Howard Berman Ph D., has been the Chairman and Chief Executive Officer of Coya Therapeutics, Inc. since 2020. Dr. Berman gained corporate experience with increasing responsibilities and positions as a...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & CEO | 4.3yrs | US$598.13k | 6.5% $ 9.3m | |
| CFO & COO | 2.1yrs | US$680.75k | 0.048% $ 68.6k | |
| President & Chief Medical Officer | less than a year | no data | no data | |
| Chief Technical Officer | 2.4yrs | no data | no data | |
| Senior Vice President of Regulatory Affairs | less than a year | no data | no data | |
| Head of Neuroinflammation Platform | no data | no data | no data | |
| Chief Business Development Officer | 1.1yrs | no data | no data |
1.6yrs
Average Tenure
62yo
Average Age
Erfahrenes Management: COYADas Führungsteam des Unternehmens gilt nicht als erfahren ( 1.3 Jahre durchschnittliche Betriebszugehörigkeit), was auf ein neues Team schließen lässt.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & CEO | 4.3yrs | US$598.13k | 6.5% $ 9.3m | |
| Independent Director | 3.1yrs | US$22.21k | 0.068% $ 98.0k | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 2.8yrs | US$22.20k | 0.12% $ 171.3k | |
| Independent Director | 2.8yrs | US$21.48k | 0.014% $ 19.6k | |
| Clinical Advisor | less than a year | no data | no data | |
| Independent Director | 2.9yrs | US$22.22k | 0.068% $ 98.0k | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | less than a year | no data | no data |
2.8yrs
Average Tenure
61yo
Average Age
Erfahrener Vorstand: COYADie Vorstandsmitglieder gelten nicht als erfahren ( 2.5 Jahre durchschnittliche Amtszeit), was auf einen neuen Vorstand hindeutet.